A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

NCT07692048 · clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
21
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Sichuan University